

| DATE | 8 AM - 9 AM | 9 AM -10 AM | 10 AM - 11 AM | 11 AM - 12 NOON | 12 PM - 1 PM | 1 PM- 2 PM | 2 PM- 3 PM | 3 - 4 PM | | | |
|-----------------|---|---|--|---|--|-------------|---|--|--|--|--|
| Mon1/3/21 | CLINICAL POSTING | | | Describe pharmacology & pharmacotherapeutics PH 1.1 (L) | Describe the basis of EBM & TDM PH1.2 (L) | 1 - 2 | PA 1- Introduction to pathology (L) | | | | |
| TUE 2/3/21 | CLINICAL POSTING | | | PA 2.1 - (L) Demonstrate the knowledge of the causes, mechanisms, types and effects of cell injury and their clinical significance (core) | PA 2.6 (L) -Describe and discuss cellular adaptations: atrophy, hypertrophy, hyperplasia, metaplasia, dysplasia (core) | | Introduction to Microbiology MI 1.1 L Morphology of bacteria MI 1.1 L | | | | |
| Wed 3/3/21 | CLINICAL POSTING | | | 11-1pm Overview of Bacterial infections & Taxonomy MI 1.1 L | | | Enumerate and identify drug formulations and drug delivery systems PH1.3 (SGD) | Enumerate and identify drug formulations and drug delivery systems PH1.3 (SGD) | | | |
| Thu 4/3/21 | CLINICAL POSTING | | | BACTERIAL GENETICS MI 1.1 L | Describe absorption, distribution, metabolism & excretion of drugs PH1.4 (L) | 1 - 2 | PA 2.2 -(L)- Describe the etiology of cell injury Distinguish between reversible & irreversible injury | C.M. 1.1 Define and describe the concept of public health | | | |
| Fri (5/3/21) | CLINICAL POSTING | | | PA 2.4 -(L) Describe and discuss cell death – types, mechanisms, necrosis, | lunch break | | Describe absorption, distribution, metabolism & excretion of drugs PH1.4 (L) | FM1.1 (LECTURE)-BASICS OF FORENSIC MEDICINE | | | |
| Saturday 6/3/21 | CM 1.2 Define Health; describe the holistic health including concept of spiritual health & the relativeness & determinants of health. | SU1.1, 1.2. Homeostasis & mediators of metabolic response. metabolic response to injury | Febrile response and influence of host immune status, risk factors and comorbidities on the febrile response IM 4.1. | OG 2.1 -ANATOMY OF THE FEMALE REPRODUCTIVE TRACT | lunch break | | AETCOM Module 2.1 Foundation of communication (2 SGD) | SPORTS | | | |
| Sun7/3/21 | 8 TO 9 | | 10 -to 11 | 11 to 12 | 12 to 1 PM | | | | | | |
| Mon8/3/21 | CLINICAL POSTING | | | Describe general principles of mechanism of drug action PH1.5 (L) | Describe general principles of mechanism of drug action PH1.5 (L) | 1 - 2 | PA 2.3 SGD - storage disorders | | | | |
| Tues 9/3/21 | CLINICAL POSTING | | | PA 2.5 & 2.7 (L)-Describe and discuss pathologic calcifications and gangrene (core) PA 2.7 Describe and discuss the mechanisms of cellular aging and apoptosis (NON CORE) | | | Microscopy & Physiology of bacteria SGD MI 1.1 | Microscopy Practicals MI 1.1 and REFLECTION | | | |
| Wed 10/3/21 | CLINICAL POSTING | | | ANTIMICROBIALS Agents, AMR MI 1.6 L | ABST Monitoring of AM therapy AMS MI 1.6 L | | Describe principles of Pharmacovigilance & ADR reporting systems PH1.6 (SGD) | Describe principles of Pharmacovigilance & ADR reporting systems PH1.6 (SGD) | | | |
| Thur 11/3/21 | CLINICAL POSTING | | | FORMATIVE ASSESSMENT | FORMATIVE ASSESSMENT | | PA 3 -(L)- Describe the pathogenesis and pathology of amyloidosis (core) | | | | |

| | | | | | | | | | | | |
|-------------------|---|--|--|---|--|-------------|--|---|--|--|--|
| Fri 12/3/21 | CLINICAL POSTING | | | PA 4.1 (L) Define & describe the general features of acute and chronic inflammation including stimuli, vascular | lunch break | | Identify and describe the management of drug interactions PH1.8 (SGD) | FM 1.2 (SDL)- HISTORY OF FORENSIC MEDICINE | | | |
| Sat13/3/21 | FM 1.2,1.4 (L)- COURTS AND LEGAL PROCEDURES | | Acute coronary syndromes- types&complications IM 2.5&IM 2.19 | | lunch break | | Module 2.1 foundation of communication -2 SGD | SPORTS | | | |
| Sunday 14/3/21 | 8 TO 9 | | 10 -to 11 | 11 to 12 | 12 to 1 PM | 1-2 PM | | 3-Apr | | | |
| Mon15/3/21 | CLINICAL POSTING | | | Describe nomenclature of drugs i.e. generic, branded drugs PH1.9 (L) | Defne,identify,describe management of ADR PH1.7 (L) | 1 - 2 | PA 4.1- (SGD)Define & describe the general features of acute and chronic inflammation including stimuli, vascular and cellular events(core) | | | | |
| Tue 16/3/21 | CLINICAL POSTING | | | PA 4.2 - SGD Enumerate and describe the mediators of acute inflammation (core) | | | Culture Media & Methods SGD MI 1.1 | Culture Media & Methods Practicals MI 1.1 | | | |
| Wed 17/3/21 | CLINICAL POSTING | | | Sterilisation & Disinfection MI 1.4 L | Sterilisation & Disinfection SGD MI 1.4, 1.5 | | Describe parts of a correct, complete and legible generic prescription. Identify errors in prescription and correct appropriately PH1.10 (SGD) | Describe parts of a correct, complete and legible generic prescription. Identify errors in prescription and correct appropriately PH1.10 (SGD) | | | |
| Thu 18/3/21 | CLINICAL POSTING | | | Identification of Bacteria Conventional & Automated SGD MI 1.1 | Describe various routes of drug administration, eg., oral, SC, IV, IM, SLPH1.11 (SGD) | | PA 5.1 (L)Define and describe the process of repair and regeneration including wound healing and its types (core) | CM 1.3 Describe the characteristics of Agent, Host and Environmental factors in health and disease and multifactorial etiology of disease. | | | |
| Fri 19/3/21 | CLINICAL POSTING | | | PA 5.1 (L)-Define and describe the process of repair and regeneration | lunch break | | Calculate the dosage of drugs for an individual patient, child elderly and patient with renal | FM 1.5,1.6,1.7 (L)- COURTS AND LEGAL PROCEDURES | | | |
| Sat20/3/21 | C.M 1.7 Health indicators (L) | | SU1.3 basic concepts of perioperative care L | Pathophysiology, manifestations of inflammatory and | OG 3.1 Physiology of ovulation L | lunch break | Module 2.1 SGD aetcom Module 2.2 Foundations of bioethics SGD | SPORTS | | | |
| Sunday 21/3/21 | 8 TO 9 | | 10 -to 11 | 11 to 12 | 12 to 1 PM | 1-2 PM | | 3-Apr | | | |
| 22/3/21 Mon | CLINICAL POSTING | | | Describe MOA, types, ADRs, indications & contraindications of adrenergic & anti-adrenergic drugs PH1.13 (L) | Describe MOA, types, ADRs, indications & contraindications of adrenergic & anti-adrenergic drugs PH1.13 | 1 - 2 | PA 6.1(L) Define and describe edema, its types, pathogenesis and clinical correlations(core) | PA 6.2 ,6.6 (L) Define and describe hyperemia, congestion , haemorrhage PA 6.6 Define and describe ischaemia/ infarction, its types, etiology, morphologic changes and clinical effects(core) | | | |
| Tue 23/3/21 | CLINICAL POSTING | | | PA 6.3 (L)Define and describe shock, its pathogenesis and its stages (core) | PA 6.4 (L)Define and describe normal haemostasis and the etiopathogenesis and consequences of thrombosis | | GRAM STAINING MI 1.2 PRACTICALS | Morphology, Cell wall theory Bacterial growth curve L forms MI 1.1 P | | | |
| Wed 24/3/21 | CLINICAL POSTING | | | Specimen collection & Transport SGD & Practicals MI 8.9 , MI 8.10 | | | Describe MOA, types, ADRs, indications and contraindications of cholinergic & anticholinergic drugs PH1.14 (L) | Describe MOA, types, ADRs, indications and contraindications of cholinergic & anticholinergic drugs PH1.14 (L) | | | |

| | | | | | | | | | | | |
|------------------|---|---|--|---|--|--|---|--|--|--|--|
| Thu 25/3/21 | CLINICAL POSTING | | | Normal Microbial Flora of Human body 1L | Describe MOA, type, ADRs, indications & contraindications of skeletal muscle relaxants PH1.15(L) - Integrated (Anesthesiology) | | PA 6.5 (L) Define and describe embolism and its causes and common types(core) | CM1.4 Describe and discuss the natural history of disease.C.M 1.5 Describe the application of interventions at various levels of prevention (SGD)(using appropriate case scenario) | | | |
| Fri 26/3/21 | CLINICAL POSTING | | | PA7.1 (L) Define and classify neoplasia. Describe the characteristics of neoplasia including gross, microscopy, biologic, behaviour and | lunch break | | Describe MOA, types, doses, ADRs, indications & contraindications of the drugs which act by modulating autacoids, | FM 1.8 (SDL)- LATEST DECISIONS/NOTIFICATION,RESOLUTION,CIRCULARS,STANDING ORDERS RELATED TO M-L PRACTICE | | | |
| Sat 27/3/21 | FM1.8(SDL)-LATEST DECISIONS/ NOTIFICATION, RESOLUTION, CIRCULARS, STANDING ORDERS RELATED TO M-L PRACTICE | SU2.1, 2.2. shock: types and principles of resuscitation. shock : management | Pathophysiology, manifestations of sepsis syndrome IM 4.7 | OG 3.1 Gametogenesis | lunch break | Module 2.3 SGD | aetcom Health care as aright SDL and SGD | SPORTS | | | |
| Sun 28/3/21 | 8 TO 9 | | 10 -to 11 | 11 to 12 | 12 to 1 PM | | | | | | |
| 29/3/21 Mon | CLINICAL POSTING | | | Describe MOA, types, doses, ADRs, indications & contraindications of the drugs which act by modulating autacoids, | Describe the mechanism/s of action, types, doses, side effects, indications and contraindications of local | 1 - 2 | 6 -SGD -EMBOLISM | PA 11.1- SGD GENETICS | | | |
| Tue 30/3/21 | | | | PA7.2 (L) Describe the molecular basis of cancer (core) | | | Sterilisation & Disinfection Visit to CSSD MI 1.5 (P) | Sterilisation & Disinfection Visit to CSSD SGD & REFLECTION | | | |
| Wed 31/3/21 | CLINICAL POSTING | | | VIRAL INFECTION An overview General Virology MI 1.1 (L) & lab diagnosis. 1 L | FUNGAL INFECTIONS An overview General Mycology Lab diagnosis MI 1.1 (L) | | Describe the general principles of chemotherapy&MOA,uses, a/e of cellwall synthesis inhibitorsPH1.42(L) | Describe the general principles of chemotherapy&MOA,uses,a/e of cellwall synthesis inhibitorsPH1.42(L) | | | |
| THU 1/4/21 | CLINICAL POSTING | | | FORMATIVE ASSESSMENT | FORMATIVE ASSESSMENT | | FORMATIVE ASSESSMENT | | | | |
| Friday 2/4/21 | CLINICAL POSTING | | | FORMATIVE ASSESSMENT AND REFLECTION | lunch break | | Describe MOA,uses,A/Eof proteinsynthesis inhibitors PH1.42(L) | FM 1.9(SGD)-MEDICO- LEGAL CERTIFICATION | | | |
| Sat 3/4/21 | CM 1.6 Describe and discuss the concepts principles of health promotion and education ,IEC and behavioural change communication | SU 3.1,3.2 Blood and blood products. Blood transfusions - Indications & complications | Describe clinical epidemiology and inherited and modifiable risk factors for common malignancies in India IM | OG 4.1 Development of fetus | lunch break | aetcom Module 2.4 Working in a health care team 2SGD | | SPORTS | | | |

| | | | | | | | | |
|------------------|--|---------|------------------|--|--|-------------|--|---|
| Sunday 4/4/21 | | | | | | | | |
| | 8 TO 9 | 9 to 10 | 10 -to 11 | 11 to 12 | 12 to 1 PM | | | |
| 5/4/21 Mon | CLINICAL POSTING | | | Describe MOA, uses, a/e of sulfonamides, quinolones PH1.42(L) | Describe drugs of abuse (dependence, addiction, stimulants, depressants, psychedelics, drugs used for criminal offences) | 1 - 2 | PA 7.3 -SGD CHEMICAL AND VIRAL CARCINOGENESIS | PA7.4 (SGD) Describe the effects of tumor on the host including paraneoplastic syndrome (core) |
| Tues 6/11/20 | CLINICAL POSTING | | | PA 7.5 (L) Describe immunology and the immune response to cancer | PA 10.1 & 10.2 (L) Define and describe the pathogenesis and pathology of malaria (core) Define and | | Categorise the infections(given) as Bacterial / Viral SGD on sources of infection, route of transmission, preventive measures, essential Infection control practices (HH) | |
| Wed 7/4/10 | CLINICAL POSTING | | | PARASITIC INFECTIONS An overview General Parasitology 1L | Epidemiology of Infections Outbreaks MI 1.3 (L) | | Describe the rational use of antimicrobials PH1.43(SGD) - Integrated (Microbiology) | Describe antibiotic stewardship programe PH1.43(SGD) - Integrated (Microbiology) |
| Thu 8/4/10 | CLINICAL POSTING | | | ANTIGEN SDL MI 1.8 | Describe the MOA, uses, A/E of antiTBdrugs PH1.44(L) | | PA 10.3 (L) Define and describe the pathogenesis and pathology of leprosy (core) | CM 1.8 Demographic profile India |
| Fri 9/4/21 | CLINICAL POSTING | | | FORMATIVE ASSESSMENT | lunch break | | Describe MDR, XDR TB & drugs acting PH1.45(L) - Integrated (Microbiology, Respiratory Medicine) | FM2.1,2,2, 2.3(LECTURE/ AUTOPSY DEMONSTRATION)- THANATOLOGY 1 |
| Sat 10/4/21 | FM 2.4,2.5,2.6 (L/AUTOPSY) - THANATOLOGY 2 | | clinical lecture | PA 11.2 (L) GENETICS Describe the pathogenesis and pathology of tumor and tumour like conditions in infancy and childhood (non | lunch break | | AETCOM Module 2.4 SDL and SGD | SPORTS |
| Sun 11/4/21 | 8 TO 9 | 9 to 10 | 10 -to 11 | 11 to 12 | 12 to 1 PM | | | |
| 12/4/21 Mon | CLINICAL POSTING | | | Describe MOA, uses, A/E, dose of antileprotics PH1.46(L) | Describe MOA, uses, A/E, dose of antimalarials, kala azar PH1.47(L) - Integrated (General Medicine) | 1 - 2 | PA 10.4 SGD INFNS Define and describe the pathogenesis and pathology of common bacterial, viral, protozoal and helminthic diseases (non core) | #integrated with CM 8.1 (Linker) |
| Tues 13/04/21 | CLINICAL POSTING | | | PA 8.1 (L) Describe the diagnostic role of cytology & its applications in clinical care(core) | PA 8.2 (L) Describe the basis of exfoliative cytology including the technique & stain used (core) | | Demonstration of Parsites of Human importance Gross/ Microscopy/ Pictures/ charts MI 1.2 (P) | |
| Wed 14/04/21 | CLINICAL POSTING | | | IMMUNOLOGY 2L Innate & Acquired immunological mechanisms in health | | | Describe MOA, uses, a/e , dose of anthelmintics PH1.47 #integrated with CM 8.1 (Linker) | Describe MOA, uses, a/e, dose of antiamoebics PH1.47 #integrated with CM 8.1 (Linker) |

| | | | | | | | | |
|----------------|--|--|---|--|--|-------------|--|--|
| Thu 15/4/21 | | | | Antigen & Antibody MI 1.8 (L) | Describe drugs in UTI PH1.48(SGD) | | PA 9.1 (L) Describe the principles and mechanisms involved in immunity (core) | M5.3 Define and describe common Nutrition related health disorders(including macronutrient, PEM Micro Iron, iron Iodine zinc ,Vitamin A) d management(2 hrs)SGD+ linker + vertical intergrat,allignment) |
| | CLINICAL POSTING | | | | | | | |
| Fri 16/4/21 | | | | PA 9.2 (L) Describe the mechanism of Hypersensitivity reactions (core) INTEGRATED | lunch break | | Describe the MOA,uses,A/E of antivirals & HIV drugs PH1.48(L) - Integrated (Microbiology) | FM2.7,2.8,2.9 (L/AUTOPSY) - THANATOLOGY 3 |
| | CLINICAL POSTING | | | | | | | |
| Sat 17/4/21 | | | | | | | | |
| | CM 5.8 Describe and discuss the importance and methods of food f | HOLIDAY | Describe the pathophysiol | OG4.1 Development of plac | | | | SPORTS |
| Sun 18/4/21 | | | | | | | | |
| | 8 TO 9 | 9 to 10 | 10 -to 11 | 11 to 12 | 12 to 1 PM | | | |
| 19/4/21 Mon | | | | Describe MOA,uses, A/Edose of antifungals PH1.48(L) | Describe drugs used in STD PH1.48(SGD) | 1 - 2 | PA 9.3 (L) Describe the HLA System and the immune principles involved in transplant and the mechanism of transplant | PA 9.6 - SGD Define and describe the pathogenesis and pathology of HIV and AIDS (core) |
| | CLINICAL POSTING | | | | | | | |
| 20/4/21 Tue | | | | PA 9.4 (L) Define Autoimmunity. Enumerate Autoimmune disorders (Core) | PA 9.7 (L) Define and describe the pathogenesis of other common autoimmune diseases(Non core) | | | Demonstration and Practicals Fungal agents KOH, Gramstain, SDA culture, LPCB mount. India Ink MI 1.1, 1.2 |
| | CLINICAL POSTING | | | | | | | |
| Wed 21/4/21 | | | | Complement MI 1.8 1L | Immune response Cell mediated Antibody mediated 1L | | Describe the mechanism/s of action, types, doses, side effects, indications and contraindications of anticancer drugsPH1.49(L) | Describe the mechanism/s of action, types, doses, side effects, indications and contraindications of anticancer drugsPH1.49(L) |
| | CLINICAL POSTING | | | | | | | |
| Thu 22/4/21 | | | | Immunoprophylaxis 1L | Describe MOA,, types, ADRs indications & contraindications of immunomodulators, organ transplantPH1.49 (L) | | PA 12.1 (SGD) Enumerate and describe the pathogenesis of disorders caused by air pollution, tobacco and alcohol (core) | CM 5.5 Describe methods of nutritional surveillance ,principles of nutritional education and bilitation in context of socio cultural factors CM 5.6Enumerate and discuss the national nutrition policy.important national nutritional programmes including ICDS |
| | CLINICAL POSTING | | | | | | | |
| Fri 23/4/21 | | | | 12.2 &12.3 (L) Describe the pathogenesis of disorders caused by protein calorie malnutrition and starvation (core) | lunch break | | Describe MOA,uses,a/e of anticoagulants PH1.25(SGD) | FM 2.10 (SGD-AUTOPSY DEMONSTRATION)- ESTIMATION OF TIME SINCE DEATH |
| | CLINICAL POSTING | | | | | | | |
| Sat 24/4/21 | FM2.11, 2.12,2.13 (L& SGD-AUTOPSY DEMONSTRATION) | SU 5.1,5.2, 5.3, 5.5. Wound healing: Normal, abnormal healing. Managenet of wound. | obesity-definition, measurement,etiology, risk factors&complications-IM 14.1-14.5 | OG 7.1Maternal Changes in Pregnancy | lunch break | | aetcom Module 2.4 Working in health care team (2 SGD) | SPORTS |
| Sun 25/4/21 | | | | | | | | |
| | 8 TO 9 | 9 to 10 | 10 -to 11 | 11 to 12 | 12 to 1 PM | | | |

| | | | | | | | |
|--------------------|---|---------|--|---|-------------|---|---|
| 26/4/21 Mon | | | Describe MOA ,uses,a/e of antiplatelets,fibrinolytics PH1.25(L) | Describe MOA ,uses,a/e of antiplatelets, fibrinolytics PH1.25(L) | 1 - 2 | PA 13.1 & PA 13.2 (L) Describe hematopoiesis and extramedullary hematopoiesis PA 13.2 Describe the role of | PA 13.3& 13.4 (L) Define and classify anemias 13.4 Enumerate and describe the investigations of anemia |
| | CLINICAL POSTING | | | | | | |
| Tuesday 27/4/21 | | | PA 14-(SGD) MHA | PA 15- (SGD) MEGALOBlastic ANEMIA | | | Antigen Antibody Reaction MI 1.8. 8.15 (P) Agglutination - slide & tube Precipitation ELISA, Rapid tests (Immunochromatography) Westernblot |
| | CLINICAL POSTING | | | | | | |
| Wed 28/4/21 | | | Integrated teaching Transplant & Cancer Immuno deficiency disorders (Pathology) | HAI, Standard and Transmission based precautions & BMW 8.5-8.8, 1.4,1.5,1.6 1L | | Describe on plasmaexpanders PH1.25(SDL) | Describe drugs acting on RAAS PH1.26(L) |
| | CLINICAL POSTING | | | | | | |
| Thu 29/4/21 | | | HAI, NSI, AMS & BMW 8.5-8.8, 1.4,1.5,1.6 (1L) | Describe pharmacotherapy of shock PH1.27(SGD) | | PA 17 - (SGD) APLASTIC ANEMIA | C.M 3.1 Describe the health hazards of air, water, noise and radiation pollution(2hrs) |
| | CLINICAL POSTING | | | | | | |
| Fri 30/4/21 | | | PA 16.1 & 16.2 (SGD) Define and classify hemolytic anemia (core) | lunch break | | Describe the mechanisms of action, types, doses, side effects of antihypertensive drugs diuretics PH1.27(L) - Integrated (General | UTOPSY DEMONSTRATION - PRESERVATION OF VISCERA FOR CHEMICAL ANALYSIS AND POST MOR |
| | CLINICAL POSTING | | | | | | |
| Sat1/5/21 | CM 17.1 Define and Describe the concept of health care of community CM 17.5 Describe health care delivery of India | | Hypertension-etiology, pathophysiology&classification IM 8.1-8.5 | lunch break | | Formative assessment | SPORTS |
| Sun 2 /5/21 | | | | | | | |
| | 8 TO 9 | 9 to 10 | 10 -to 11 | 11 to 12 | 12 to 1 PM | | |
| 3/5/21 Mon | | | Describe classification, MOA, types, doses, side effects of antihypertensivesPH1.27(L) - Integrated (General | Describe classification, MOA,types, doses, side effects of antihypertensivesPH1.27 (L)- Integrated (General | 1 - 2 | PA 16.3 - (L)Describe the pathogenesis, features, hematologic indices and peripheral blood picture of sickle cell anemia and | PA 16.4- (L) Describe the etiology pathogenesis, hematologic indices and peripheral blood picture of Acquired hemolytic anemia. Describe briefly about PNH and Autoimmune hemolytic anemia.(CORE) PA 16.7 - Describe the correct technique to perform a cross match – coombs' test (CORE) |
| | CLINICAL POSTING | | | | | | |
| Tue 4/5/21 | | | PA 18.1 - (L) NON NEO WBC Enumerate and describe the causes of leucocytosis leucopenia lymphocytosis and leukemoid reactions | 16- SGD HEMOLYTIC ANEMIAS | | | Integrated teaching (2L) Hypersensitivity , Autoimmunity (Microbiology and Pathology) |
| | CLINICAL POSTING | | | | | | |

| | | | | | | | | |
|------------------|--|---------|---|---|--|-------------|---|--|
| Wed 5/5/21 | CLINICAL POSTING | | | L Beta haemolytic Streptococcal infections Gas gangrene and infections due to Non sporing Anaerobes MI 4.3, 1.2, MI 4.1, 1.2 | SDL followed by L Actinomycosis, nocardiosis Non Venereal treponematosis Anthrax MI 4.3, 1.2. 8.13, 8.15 | | Pharmacotherapy of angina, MI,PVD PH1.28(L) - Integrated (General Medicine) | Pharmacotherapy of angina,MI,PVD PH1.28(L) - Integrated (General Medicine) |
| Thu 6/5/21 | CLINICAL POSTING | | | L & SDL Leprosy and other bacterial Skin and soft tissue infections | Pharmacotherapy of CCF PH1.29(L) | | PA 18.2 -(L) LEUKEMIA Describe the etiology, genetics, pathogenesis classification, features, hematologic features of acute and chronic leukemia INTEGRATED | Describe and enumerate principles, concepts and uses CM 7.5 Enumerate ,define ,describe and discuss epidemiological study designs |
| Friday 7/5/21 | CLINICAL POSTING | | | PA 18.2 - (L) LEUKEMIA Describe the etiology, genetics, pathogenesis classification, features, hematologic features of | lunch break | | Describe MOA,uses,a/e of antiarrhythmics PH1.30(L) | FM2.17 (SGD) - EXHUMATION |
| Sat 8/5/21 | FM2.26 (SDL)-PM FINDINGS OF STARVATION AND NEGLET | | Common cancers- genetics,risk factors, clinical presentations IM 13.1-13.4 | | lunch break | | | SPORTS |
| Sun 9/5/21 | 8 TO 9 | 9 to 10 | 10 -to 11 | 11 to 12 | 12 to 1 PM | | | |
| 10/5/21 Mon | CLINICAL POSTING | | | Hypolipidemics PH1.30(L) - Integrated (General Medicine) | Management of dyslipidemias PH1.31 (SDL) | 1 - 2 | PA 19.1 (SGD) Enumerate the causes and describe differentiating features of Lymphadenopathy | PA 19.2 (SGD) Describe the pathogenesis and pathology of Tuberculous Lymphadenitis |
| Tue 11/5/21 | CLINICAL POSTING | | | PA 19.4 (L) Describe and discuss pathogenesis, pathology and the differentiating features of HL and NHL | | | | PRACTICALS, DOAP - SKILLS LAB HAI, NSI, AMS & BMW 8.5-8.8, 1.4.1.5,1.6 P |
| Wed 12/5/21 | CLINICAL POSTING | | | L & SDL Viral Exanths and other cutaneous Viral infections MI 4.3, 8.15 | | | Describe drugs used in bronchial asthma,COPD PH1. 32(L) - Integrated (Respiratory Medicine) | Describe drugs used in bronchial sthma,COPD PH1.32(L) - Integrated (Respiratory Medicine) |
| Thu 13/5/21 | CLINICAL POSTING | | | FORMATIVE ASSESSMENT | FORMATIVE ASSESSMENT | | FORMATIVE ASESMENT | HOLIDAY |
| Fri 14/5/21 | CLINICAL POSTING | | | PA 19.6 -(L) SPLENOMEGALY | lunch break | | Describe Pharmacotherapy of cough PH1.33(SDL) | FM2.20, 2.21 (L) - AUTOPSY DEMONSTARTION- MECHANICAL ASPHYXIA |

| | | | | | | | |
|-------------------|---|--|--|---|---|---|--|
| Sat 15/5/21 | 11.1 Enumerate & describe the presenting features of patient with occupational illness including agriculture.(health hazards ,pneumoconiosis) | SU 6.1, 6.2. surgical infections : etiology and Prophylactic and therapeutic a | Anemia definition,causes, classification,and symptoms IM 9.1&9.2 | OG 6.1Diagnosis of pregnancy | lunch break | aetcom Module 2.5 Bioethics contd 2 SGD | SPORTS |
| Sunday 16/5/21 | 8 TO 9 | 9 to 10 | 10 -to 11 | 11 to 12 | 12 to 1 PM | | |
| 17/5/21 Mon | CLINICAL POSTING | | | Describe MOA,uses,a/e of corticosteroids PH1.38(L) | Describe MOA,uses,a/e of corticosteroids PH1.38 (L) | 1 - 2 | PA 21.1, 21.3 (L) Describe normal hemostasis (core) PA 21.3 Differentiate Platelet from Clotting disorders based on clinical PA 21.2 SGD Classify and Describe the etiology, pathogenesis and pathology of vascular and platelet disorders including ITP and hemophilia (core) |
| Tue 18/5/21 | CLINICAL POSTING | | | PA 21.4 (L) Define and describe Disseminated Intravascular Coagulation, its Laboratory findings and diagnosis of DIC (core) | | | INTERNAL ASSESSMENT I General Microbiology & Immunology |
| Wed 19/5/21 | CLINICAL POSTING | | | SDL - SYMPOSIUM Parasitic infections Leishmaniasis, (Kala azar and Cutaneous), Cutaneous larva migrans, subcutaneous tissue nematodes, Filariasis MI 4.2, 4.3, 8.13, 8.15 | SDL - SYMPOSIUM Fungal infections Superficial and subcutaneous mycoses Penicillium marneffeii, Cutaneous manifestations of Systemic mycosis MI 4.2, 4.3, 8.13, 8.15 | | Describe the mechanisms of action, types, doses, side effect of sex hormones PH1.37(SGD) Describe the mechanisms of action, types, doses, side effect of sex hormones PH1.37(SGD) |
| Thu 20/5/21 | CLINICAL POSTING | | | L Infective Syndromes of RT & Streptococcal pharyngitis MI 6.1 | Describe MOA,uses,a/e of uterine relaxantsPH1.41(SGD) | | PA 21.5 SGD Define and describe Disseminated Intravascular Coagulation, its Laboratory findings and diagnosis of Vitamin K deficiency (core) C M 11.3 Enumerate and describe specific occupational health hazards,their risk factors, preventive measures. |
| Friday 21/5/21 | CLINICAL POSTING | | | PA 20.1 (L) Describe the features of plasma cell myeloma | lunch break | | Describe drugs used for infertility &erectile dysfunctionPH1.40(SGD) FM 2.22,2.23(L) - AUTOPSY DEMONSTARTION- MECHANICAL ASPHYXIA |
| Sat22/5/21 | FM 2.25 (SGD) - THERMAL DEATH | 14.1, 14.2, 14.3. sterilization and disinfection. surgical approaches, incisions & instruments in general surgery. | Define &classify diabetes, Describe and discuss the epidemiology, pathogenesis,risk factors&clinical evolution | OG 8.1&8.2&35.5 antenatal care, assessment of period of gestation; screening for high risk factors | lunch break | aetcom Module 2.6 Bioethics contd 2 SGD | SPORTS |
| Sunday 23/5/21 | 8 TO 9 | 9 to 10 | 10 -to 11 | 11 to 12 | 12 to 1 PM | | |
| 24/5/21 Mon | CLINICAL POSTING | | | Drugs used for contraception PH1.39(SGD) | Drugs used for contraception PH1.39 (SGD) | 1 - 2 | PA 22 (SGD) Blood banking and transfusion |

| | | | | | | | |
|-------------|--|-----------------|---|--|---|--|--|
| Tue 25/5/21 | CLINICAL POSTING | | | PA23.2 (SGD) Describe abnormal findings in body fluids in various disease states | PA34.1 - 3 (L) SKIN | | 1L and 1 SGD infective syndromes of Skin, Soft tissue and Musculoskeletal system MI 4.1, 4.2, 4.3 and Staphylococcal infections MI 1.2 |
| Wed 26/5/21 | CLINICAL POSTING | | | L Infective Syndromes of RT & Streptococcal pharyngitis MI 6.1 | 1 L Diphtheria, Pertussis MI 6.1, 6.2 | | Describe mechanism of action, classes, side effects, indications and contraindications of antidiabetic drugs PH1.36(L) - Integrated (General Medicine) Describe mechanism of action, classes, side effects, indications and contraindications of antidiabetic drugs PH1.36(L) - Integrated (General Medicine) |
| Thu 27/5/21 | CLINICAL POSTING | | | 1 L RTI due to Pseudomonas, Acinetobacter, Burkholderia & Others MI 6.1, 6.3, 4.3 | Describe MOA, uses, a, e of drugs used in thyroid disorders PH1.36(L) | | PA33.1 - 2 (L) OSTEOMYELITIS AND BONE TUMOURS CM11.2 Describe the role, benefits and functioning of the ESI scheme CM 11.4 Describe the principles of ergonomics in health preservation |
| Fri 28/5/21 | CLINICAL POSTING | | | PA33.1 - 2 (L) OSTEOMYELITIS AND BONE TUMOURS | lunch break | | Describe MOA, uses, a, e of drug used in osteoporosis PH1.36(SGD) FM 2.26 (SGD /AUTOPSY DEMONSTRATION)- INJURIES DUE TO PHYSICAL AGENTS 1 |
| Sat 29/5/21 | CM 20.2 Describe various issues during outbreaks and their prevention in the context of covid-19 | SU9.1 endoscopy | Define, discuss, describe & distinguish community acquired pneumonia, nosocomial pneumonia & aspiration | OG 8.3 Obstetric examination | lunch break | aetcom Module 2.6 Bioethics contd SDL and 2 SGD | SPORTS |
| SUN 30/5/21 | | | | | | | |
| MON 31/5/21 | CLINICAL POSTING | | | es, a/e of General anaesthetics PH1.18 (L) - Integrated (/ | | | PA 33.3- SGD- Soft tissue tumours |
| TUE 1/6/21 | CLINICAL POSTING | | | PA 33.4- SDL PAGETS DISEASE | PA 33.5- SDL RHEUMATOID ARTHRITIS | | 1L + 1 SGD Tuberculosis & RI with NTM bacilli MI 6.1 |
| 2/6/21 WED | CLINICAL POSTING | | | 1L Bacterial Atypical pneumonia Mycoplasma, Chlamydia, Legionella & others MI 6.1 & 6.3 | 1 SDL & SGD Myxovirus infections of RT MI 6.1 | | PH2.1 Demonstrate the understanding of various dosage form (SGD) |
| THU 3/6/21 | CLINICAL POSTING | | | 1L COVID 19 & other Corona virus MI 6.1 | Describe MOA, uses, a/e of sedative | | PA 26.1, 26.2- (L) RESPIRATORY SYSTEM - Pneumonia, Lung abscess CM 8.1 Prevention and control of Corona virus and other acute respiratory infections |

| | | | | | | | | |
|-------------|---|---|---|--|--|--|--|--|
| FRI 4/6/21 | | | | PA 26.3- (L) RESPIRATORY SYSTEM- OAD | | | MOA,uses,a/e,CI of antidepressants | FM 2.26 (SGD /AUTOPSY DEMONSTRATION)- INJURIES DUE TO PHYSICAL AGENTS 2 |
| | CLINICAL POSTING | | | | | | | |
| SAT5/6/21 | FM 2.35 (SGD/AUTOPSY DEMO)-MAKING OPINION AN | SU 9.1, 9.2. early detection of cancer and multidisciplinary management. Breaking bad news in cancer treatment. | Describe and discuss COPD in elderly IM 24.10 | OG 8.1,8.6&8.8 ANTENATAL CARE | | | Aetcom Module 2.6 Bioethics Contd SDL and SGD | SPORTS |
| SUN6/6/21 | | | | | | | | |
| MON7/6/21 | | | | PH1.19 Describe MOA,uses,a,e,CI of antiepileptics (L) - Integrated (Physiology, Psychiatry) | | | | PA 2.8- (P) Cell injury |
| | CLINICAL POSTING | | | | | | | |
| TUE8/6/21 | | | | PA 26.5, 26.7- SGD RESPIRATORY SYSTEM- Occupational lung diseases, mesothelioma | | | | Practical Demonstration - DOAP Gram Staining MI 8.15, 6.2, 6.3 |
| | CLINICAL POSTING | | | | | | | |
| WED9/6/21 | | | | 1 Flipped class Miscellaneous Viral Infections of RT MI 6.1, 6.2 | Feedback & Reflections SSTI & RTI (SGD) | | | PH2.1Demonstrate the understanding of various dosage form (SGD) |
| | CLINICAL POSTING | | | | | | | |
| THU 10/6/21 | | | | 1L CVS infections Infective Endocarditis, A/c Rheumatic fever & others MI 2.1, 2.2 | PH1.19 Describe MOA, uses,a/e,CI OF Opioids (L) | | PA 26.3- (L) RESPIRATORY SYSTEM-OAD | CM 3.3Describe the aetiology and basis of water borne diseases /jaundice/hepatitis/ diarrheal diseases |
| | CLINICAL POSTING | | | | | | | |
| FRI 11/6/21 | | | | PA 26.4- (L) RESPIRATORY SYSTEM- TB INTEGRATED | | | PH1.19 Describe MOA,uses, a/e,CI of Opioids (L) | FM 3.3 , 3.4 (L / AUTOPSY) - MECHANICAL INJURIES 1 |
| | CLINICAL POSTING | | | | | | | |
| SAT12/6/21 | CM 8.1 Discuss the epidemiological and control measures including the use of essential laboratory test at the primary care level for Small pox ,chicken pox | | | OG 1.3,9.1Miscarriage | | | | SPORTS |
| SUN 13/6/21 | | | | | | | | |
| MON 14/6/21 | | | | PH1.19 Describe MOA,uses, a/e,CI of antipsychotics (L) | PH1.19 Drugs used in neurodegenerative disorders (SGD) | | | PA 3.2- (P) AMYLOIDOSIS |
| | CLINICAL POSTING | | | | | | | |

| | | | | | | |
|----------------|--|---|--|---|---|--|
| TUE 15/6/21 | CLINICAL POSTING | | PA 26.6- (L) RESPIRATORY SYSTEM- LUNG TUMOURS | PA 27.1- (L)- CVS- ARTERIOSCLEROSIS | | 1 L, 1 SGD Enteric Fever - S.Typhi & S.Paratyphi MI 3.3 |
| WED 16/6/21 | CLINICAL POSTING | | 1 L Leptospirosis MI 8.1 | 1 SGD Brucellosis, Borreliosis MI 8.1 | | PH2.2 Prepare ORS and explain its use (SGD) |
| THU 17/6/21 | CLINICAL POSTING | | 1L Rickettsial infections MI 1.1 | PH1.20 Alcoholand ethyl, methyl alcohol poisonin SGD | PA 27.4- (L)- CVS- RHEUMATIC FEVER INTEGRATED WITH MICRO MI 12.3 | CM 8.1 Prevention &Control of Rickettsial infections |
| FRI 18/6/21 | CLINICAL POSTING | | PA 27.6, 27.7- (L)- CVS- INFECTIVE ENDOCARDITIS, PERICARDITIS, PERICARDIAL EFFUSION | | PH1.20 Alcoholand ethyl, methyl alcohol poisonin SGD | FM 3.5,3.6 (L / AUTOPSY) - MECHANICAL INJURIES 2 |
| SAT 19/6/21 | FM 3.7 (L/AUTOPSY)-INJURIES CONT...,CERTIFICATION OF WOUND | SU 6.3, 6.4, 6.5. Measures to reduce Surgical site classification of surgical wound universal precautions. | Describe the initial approach to stabilisation of the patient who presents with poisoning IM 21.1 | OG9.5 Hyperemesisgravidarum | Aetcom module 2.7 bioethics contd SDL and SGD | SPORTS |
| SUN 20/6/21 | | | | | | |
| MON 21/6/21 | CLINICAL POSTING | | PH1.22 Describe drugs of abuse SGD | PH1.23 Describe mechanism of deaddiction SGD | | PA 4.4- (P)- ACUTE AND CHRONIC INFLAMMATION |
| TUE 22/6/21 | CLINICAL POSTING | | PA 27.5- (L) CVS- ISCHEMIC HEART DISEASE INTEGRATED WITH IM 2.5 | | | 1 SGD, 1 DOAP - SKILLS LAB Sepsis, CRBSI, IE, RHD Blood sample collection for culture MI 8.15, 2.3 |
| WED 23/6/21 | CLINICAL POSTING | | 1L Blood stream infections causing anaemia MI 2.1, 2.2, | 1L Malaria & Babesiosis MI 2.5, 8.16 INTEGRATED | | PH2.2 Prepare ORS and explain its use (SGD) |
| THU 24/6/21 | CLINICAL POSTING | | 1L KALA AZAR Trypanosomiasis, & other parasitic MI 2.5, 8.16 | PH1.52 Describe pharmacotherapy of poisoning (L) -Integrated (General Medicine) | PA 27.2, 27.3- (SGD) CVS- ANEURYSM, HEART FAILURE | CM 8.1 Epidemiologyand control measures at the primary care level for Leishmaniasis IL (Micro) |
| FRI 25/6/21 | CLINICAL POSTING | | PA 27.9, 27.10- (SGD) CVS- CARDIOMYOPATHY, SYPHILIS | | PH1.53 Describe heavy metal poisoning and chelating agent SGD | FM 3.8(L/AUTOPSY)- MECHANICAL INJURIES AND WOUNDS -WEAPON EXAMINATION |

| | | | | | | | |
|-------------------|--|---|--|---|---|---|---|
| SAT 26/6/21 | CM 8.1 Epidemiology & Control of Leptospirosis | | Discuss and describe epidemiology, antecedents and risk factors for atherosclerosis and IHD IM 2.1. Discuss the aetiology of risk factors both modifiable and non modifiable of atherosclerosis and IHD IM 2.2. Discuss and describe the pathogenesis, natural history and | OG 9.3 Acute abdomen in early pregnancy (Ectopic pregnancy) | | Aetcom module 2.7 Bioethics contd | SPORTS |
| SUN 27/6/21 | | 12.1, 12.2, 12.3 malnutrition in surgery patient Fluid and electrolyte replacement Nutritional support in surgery | | | | | |
| MON 28/6/21 | CLINICAL POSTING | | | PH1.54 Describe vaccines and their uses SGD | PH1.35 Drugs used in hematological disorders SGD | | PA 6.7- (P) HEMODYNAMIC DISORDERS |
| TUE 29/6/21 | CLINICAL POSTING | | | PA36.1- (SGD)- EYE | PA 24.2, 24.3- (SGD) GIT- PEPTIC ULCER DISEASE | | 1L & 1 Practicals Filaria & Demonstration of haematoparasites MI 2.5, 8.16 |
| WED 30/6/21/21 | CLINICAL POSTING | | | 1L HIV MI 2.7 | 1L HIV MI 2.7 INTEGRATED (Medicine) | | PH2.3 Demonstrate the appropriate setting up of an IV drip in a simulated environment (SGD) |
| THU 1/7/21 | CLINICAL POSTING | | | 1L VHF Dengue, CHIK, KFD & others | PH1.34 Drugs in APD SGD | PA 24.4 (L) GIT- CA STOMACH | CM 8.1 Discuss the epidemiology and control measures of Dengue, CHIK, KFD |
| FRI 2/7/21 | CLINICAL POSTING | | | PA 24.7 (L) GIT- CA COLON | | PH1.34 Antiemetics (L) | FM 3.9(SGD)- FIREARM INJURIES 1 |
| SAT 3/7/21 | FM 3.9 (SGD)- FIREARM INJURIES 2 | 10.1, 10.2 Principles of peri operative management Informed consent | Describe and discuss the a | OG 14.1, 14.2, 14.3 Pelvis, Lie, Presentation | | Aetcom Module 2.7 Bioethics contd Aetcom Module 2.8 What does it mean to be a family member of a sick patient | SPORTS |
| SUN 4/7/21 | | | | | | | |
| MON 5/7/21 | CLINICAL POSTING | | | PH1.34 Laxatives, antidiarrhoeals, drugs in IBD (SGD) | PH1.57 Describe drugs used in skin disorders SDL | | PA 24.1- (SGD) -GIT- ORAL CANCERS AND SALIVARY GLAND TUMORS |

| | | | | | | |
|----------------|---|---|---|---|---|---|
| TUE 6/7/21 | CLINICAL POSTING | | | PA 24.5,24.6- (SGD/SYMPOSIA) GIT- IBD AND TB | | 1 SGD + 1 Practicals Systemic Mycosis & Demonstration of Viral diagnostic tests MI 8.15, 2.7 |
| WED 7/7/21 | CLINICAL POSTING | | | 1L Gastrointestinal Infective Syndrome and Shigella MI 3.1 | 1SGD Food Poisoning: S.aureus, Bacillus cereus, Clostridium botulinum and others MI 3.5 | PH3.1 Write a rational and correct legible generic prescription and communicate to the patient SGD |
| THU 8/7/21 | CLINICAL POSTING | | | 1SDL and 1L Diarrhoeogenic E.coli, NTS and yersiniosis, Cholera, halophilic Vibrio and Aeromonas Infections MI 3.1 | PH1.58 Describe drugs used in ocular disorders SDL | PA 25.1, 25.2- HEPATOBILIARY SYSTEM (L)- JAUNDICE; HEPATIC FAILURE INTEGRATED WITH IM 5.4,6 CM 8.1 Describe the principles and enumerate the measures to control an outbreak of food poisoning . |
| FRI 9/7/21 | CLINICAL POSTING | | | PA 25.4, 24.5- HEPATOBILIARY SYSTEM (L)- CIRRHOSIS, PORTAL HYPERTENSION | | PH1.59 Describe and discuss FDC, OTC, herbal medicines SDL FM 3.10 (L) - FIREARM INJURIES |
| SAT 10/7/21 | CM 8.1 Epidemiology & control of Cholera | | | OG 13.1,14.2&13.5 NORMAL LABOUR- MECHANISM, CONDUCT OF LABOUR, PARTOGRAM | | SPORTS |
| SUN 11/7/21 | n | | | | | |
| MON 12/7/21 | CLINICAL POSTING | | | PH1.60 Describe pharmacogenomics and economics SGD | PH3.2 Perform and interpret critical appraisal of given prescription SGD | PA 8.3- (P) CYTOLOGY |
| TUE 13/7/21 | CLINICAL POSTING | | | PA 28.1- 28.5- (L) URINARY TRACT- RENAL FAILURE, GLOMERULONEPHRITIS | | SGD/Practical: Stool microscopy, Staining, Intestinal Protozoans, Giardiasis, Coccidian Parasitic Infections, blastocystosis and others MI 1.2, 3.1,3.2 |
| WED 14/7/21 | CLINICAL POSTING | | | 1 SGD & SDL Miscellaneous Bacterial Infections of gastrointestinal System: Helicobacter, Campylobacter and Clostridium difficile Infections, Viral gastroenteritis (Rotaviruses and others) MI 3.6 & MI3.1 | 1L Intestinal Protozoan Infections: Amoebiasis and balantidiasis MI3.1 | PH4.1 Administer drugs through various routes DOAP |
| THU 15/7/21 | CLINICAL POSTING | | | 1L Intestinal Cestodes and Trematodes MI3.1 | PH1.62 Antiseptics and disinfectants SDL | PA 28.6, 28.8, 28.9- (L) URINARY TRACT- IgA nephropathy, Tubulo interstitial diseases CM 8.1 Describe the principles and enumerate the measures to control intestinal parasitic infections . |
| FRI 16/7/21 | CLINICAL POSTING | | | PA 28.12- (L) URINARY TRACT- CYSTIC RENAL DISEASES | | PH2.4 Demonstrate the correct method of dosage calculation in special situations (SGD) FM 3.11(SGD/AUTOPSY)- REGIONAL INJURIES 1 |
| SAT 17/7/21 | CM 8.1 Discuss the control measures of Acute diarrhoeal diseases in the Community | SU 10.3 Emergency lifesaving surgical procedures. | OG 17.1&19.1 Physiology of lactation & puerperium | IM5.6 Pathophysiology, clinical evolution and complications of cirrhosis and portal hypertension | | Aetcom Module 2.8 What does it mean to be a family member of a sick patient SPORTS |

| | | | | | | |
|----------------|--|------------------------------|--|---|---|--|
| SUN 18/7/21 | | | | | | |
| MON/19/7/21 | CLINICAL POSTING | | PH1.64 Clinical trials and GCP (SGD) | PH2.5 drug development (SDL) | | PA 13.5- (P) - Peripheral smear preparation and interpretation in anemia |
| TUE 20/7/21 | CLINICAL POSTING | | PA 28.12 SYMPOSIA RENAL CYSTIC DISEASES | | | P/SGD -Protozoans: Nematodes, Trematodes, Cestodes and others MI 3.1,3.2 |
| WED 21/7/21 | CLINICAL POSTING | | 1L Intestinal Nematode Infections: Trichuris, Enterobius, hookworm, Strongyloides, Ascaris and others MI 3.1 | 1L infective syndromes of hepatobiliary system Viral hepatitis Introduction MI 3.7 (ALIGNED) | | PH4.1 Administer drugs through various routes DOAP |
| THU 22/7/21 | CLINICAL POSTING | | 1L Viral Hepatitis Yellow Fever & others MI 3.7 (ALIGNED) | PH2.5 Pharmacovigilance activities (SGD) | PA 28.14- 28.16- (L) URINARY TRACT- RENAL TUMOURS, UROTHELIAL TUMOURS | CM 8.1 Describe the principles and enumerate themeasures to control intestinal parasitic infections . |
| FRI 23/7/21 | CLINICAL POSTING | | PA 25.3- HEPATOBIILIARY SYSTEM (SGD)- HEPATITIS INTEGRATED WITH MI 3.7 AND IM 5.12, 6 | | PH4.2 Demonstrate the effects of drugs on BP SKILL LAB CAL (SGD) | FM 3.11(SGD/AUTOPSY)- REGIONAL INJURIES 2 |
| SAT 24/7/21 | CM 8.1 Epidemiology and control of Viral Hepatitis (ALIGNED) | SU 10.1, Perioperative care. | Epidemiology, microbiology, immunology and clinical evolution of viral hepatitisIM 5.4 | OG 10.1APH | Aetcom module 2.8 | SPORTS |
| SUN 25/7/21 | | | | | | |
| MON 26/7/21 | CLINICAL POSTING | | PH4.2 Demonstrate the effects of drugs on BP SKILL LAB CAL (SGD) | | | PA 14.3- (P)- PS IN MHA |
| TUE 27/7/21 | CLINICAL POSTING | | PA 28.7, 28.15- (SGD) URINARY TRACT- DIABETIC NEPHROPATHY, MYELOMA KIDNEY, THROMBOTIC ANGIOPATHIES | | | 1 SGD + 1 Practical Parasitic infections of Hepatobiliary system Amoebic Liver abscess, Hydatid disease, Fasciola hepatica, Clonorchis, Opisthorchis & others MI 3.1, 1.1 |
| WED 28/7/21 | CLINICAL POSTING | | 1 SGD Ocular & Ear infections MI 1.1 | L1 Infective syndromes of CNS Meningitis & Encephalitis MI 5.1, 5.2 | | PH3.1 Write a rational and correct legible generic prescription and communicate to the patient SGD |
| THU 29/7/21 | CLINICAL POSTING | | 1L Acute bacterial Meningitis (Pyogenic) N.meningitidis, Pneumococci, Hib GBS, Listeria, E.coli & Others MI 5.1 | PH4.2 Demonstrate the effects of drugs on BP SKILL LAB CAL (SGD) | PA 35.1, 35.2- (L)- CNS- MENINGITIS AND TUMOURS | CM 8.1 Epidemiology and prevention of bacterial meningitis |

| | | | | | | | |
|----------------|--|--|--|--|--|-------------------------------|---|
| FRI 30/7/21 | CLINICAL POSTING | | | PA 28.13- (SGD) - URINARY TRACT- OBSTRUCTIVE UROPATHY | | FORMATIVE ASSESSMENT | FM 3.20(SGD) - DISPUTED PATERNITY AND MATERNITY |
| SAT 31/7/21 | FM 8.1,8.2 (SDL) - INTRODUCTION TO TOXICOLOGY | SU 10.3 Principles of post operative care for minor surgical procedures. | OG 12.1 Hypertensive disorders in pregnancy | IM10.1 Define,describe and diffrentiate between acute and chronic renal failure 10.3 Describe the pathophysiology and causes of pre renal, renal and post renal ARF | | REFLECTION | SPORTS |
| SUN 1/8/21 | | | | | | | |
| MON 2/8/21 | CLINICAL POSTING | | | PH3.6 To demonstrate how to optimise interaction with representative to get authentic information SGD | | | PA 14.3- (P)- PS IN MACROCYTIC ANEMIA |
| TUE 3/8/21 | CLINICAL POSTING | | | PA 28.10- (SGD) URINARY TRACT- PYELONEPHRITIS | | | 1 SGD, Chronic Bacterial meningitis9Tubercular,Spirochaetal, Lyme disease etc) 1 practical Agents of Pyogenic meningitis (N.meningitidis, S.pneumoniae, H.influenzae) & Agents of Neonatal meningitis- E coli, GBS. MI 5.3 |
| WED 4/8/21 | CLINICAL POSTING | | | 1L Poliomyelitis & Other agents of Viral Meningitis (Coxsackievirus) MI 5.1 , 8.16 | 1 L Viral Encephalitis Rabies, HSV MI 5.2 | | PH5.1 Communicate with patient with ethics & empathy SGD |
| THU 5/8/21 | CLINICAL POSTING | | | 1L Encephalitis Arboviral (JE,WestNile, KFD) NIPAH, Slow Virus, PRIONS MI 5.2 (ALIGNED) | PH 3.2 Prescription audit SGD | PA 29.1-29.4- (L) MGS | CM 8.1Discuss the epidemiology and control measures including the use of essential laboratory test for RABIES |
| FRI 6/8/21 | CLINICAL POSTING | | | PA 29.5- (SDL) MGS- PROSTATITIS | | PH 3.2 Prescription audit SGD | FM 8.3,8.4,8.5,8.6 (L/AUTOPSY) - GENERAL TOXICOLOGY 1 |
| SAT 7/8/21 | CM 8.1 Epidemiology and prevention of JE & West Nile fever (ALIGNED) | SU 9.1. investigations in surgical patients | Describe and discuss the response and influence of host immune status,risk factors and comorbidities on zoonotic diseases and nonfebrile infectious disease(tetanus) IM 25.1. Common causes, pathophysiology and manifestations of these | OG 12.2Anemia in pregnancy | | REFLECTION AND LEARNING | SPORTS |

| | | | | | | |
|-------------|------------------|---|---|---|--|--|
| SUN 8/8/21 | | | | | | |
| MON 9/8/21 | CLINICAL POSTING | | PH3.2 Prescription audit SGD | | | PA 14.3- (P)- PS IN hemolytic anemia |
| TUE 10/8/21 | CLINICAL POSTING | | PA 30.7, 30.8-(SGD) - FGS- Endometriosis, adenomyosis | | | 1 SGD , 1 practicals Lab Diagnosis of Pyogenic meningitis & Cryptococcal Meningitis (Choose & Interpret the laboratory Report) MI 5.3, 8.15 |
| WED 11/8/21 | CLINICAL POSTING | | 1SGD Parasitic CNS Infections Neurocysticercosis, Free Living Amoeba, Toxoplasmosis & Other MI 5.1, 5.2 | 1 SGD Fungal CNS infections Cryptococcal & Others MI 5.1, 5.2 | | PH3.2 Prescription audit SGD |
| THU 12/8/21 | CLINICAL POSTING | | 1L Tetanus & Botulism MI 4.1 | PH3.3 Critical evaluation of drug promotional literature SGD | | PA 30.2 ,30.9 (L) - FGS- CA ENDOMETRIUM CM 8.1 Epidemiology &prevention of Tetanus and Trachoma |
| FRI 13/8/21 | CLINICAL POSTING | | PA 30.1, 30.3 -(L) - FGS- CA CERVIX, SMOOTH MUSCLE TUMOURS OF UTERUS | | | PH3.3 Critical evaluation of drug promotional literature SGD FM 8.7,8.8,8.9,8.10 (L/AUTOPSY) - GENERAL TOXICOLOGY 2 |
| SAT 14/8/21 | | FM 9.1 (SGD-SEMINAR) - CHEMICAL TOXICOLOGY1 | OG 12.3GDM | | | SPORTS |
| SUN 15/8/21 | | | | | | |
| MON 16/8/21 | CLINICAL POSTING | | PH3.3 Critical evaluation of drug promotional literature SGD | | | PA 19.3- (P) TB LYMPHNODE |
| TUE 17/8/21 | CLINICAL POSTING | | PA 30.5 -(SGD) - FGS- GESTATIONAL TROPHOBLASTIC DISEASES | | | 1L Urinary Tract Infection - Introduction and overview on various pathogens and infective syndroms of Urinary tract (E.coli) MI 7.3 1 SGD Lab. diagnosis Of UTI |
| WED 18/8/21 | CLINICAL POSTING | | 1 SGD Klebsiella, Psudomonas, Proteus Staph.saprophyticus & Others & CAUTI MI 7.3 | 1 SGD TB Nephritis MI 7.3 | | PH3.3 Critical evaluation of drug promotional literature SGD |
| THU 19/8/21 | CLINICAL POSTING | | 1 L Infective Syndromes of Genital Tract Syphilis MI 7.1, 7.2 | PH3.8 Communicative exercises (SGD) | | FORMATIVE ASSESSMENT CM 8.1 Epidemiology and prevention of Sexually transmitted infections |

| | | | | | | | |
|----------------|---|--|--|---|---|---|---|
| FRI 20/8/21 | CLINICAL POSTING | | FORMATIVE ASSESSMENT | | | PH3.8 Communicative exercises (SGD) | FM 9.1 (SGD-SEMINAR) - CHEMICAL TOXICOLOGY2 |
| SAT 21/8/21 | Community Medicine -Internal Assessment I | | OG 15.1CAESAREAN SECTION | | AETCOM - COMMUNICATION AND PATIENT CARE | | SPORTS |
| SUN 22/8/21 | | | | | | | |
| MON 23/8/21 | CLINICAL POSTING | | | | | FORMATIVE ASSESSMENT | |
| TUE 24/8/21 | CLINICAL POSTING | | PA 30.4-(L) - FGS- OVARIAN TUMOURS | PA 30.6-(SDL) - FGS- CERVICITIS | | 1 SGD, 1 Practical Lab Diagnosis of UTI Sample collection, Transport, Lab Processing, Interpretation of report MI 7.3 , 8.15 | |
| WED 25/8/21 | CLINICAL POSTING | | SDL + 1 SGD Gonorrhoea & NGU MI 7.2 (SDL- Bacterial vaginosis, Trichomoniasis, Vaginal Candidiasis) | 1 L Lab diagnosis of STI (Syphilis, Gonorrhoea, Trichomoniasis, Candidiasis & others) MI 7.1, 7.2 | | PH3.5 To prepare and explain a list of P drugs for a case (SGD) | |
| THU 26/8/21 | CLINICAL POSTING | | 1 L Ulcerative Genital diseases soft chancre, LGV, Genital herpes, Granuloma inguinale etc MI 7.1, 7.2 | PH3.5 To prepare and explain a list of P drugs for a case (SGD) | | PA 30.4 SGD /SYMPOSIA OVARIAN TUMOURS | CM 8.1Discuss the epidemiology and control measures for Hepatitis B and C |
| FRI 27/8/21 | CLINICAL POSTING | | PA 31.2- (L)- BREAST- CA BREAST | | | PH3.5 To prepare and explain a list of P drugs for a case SGD | FM 9.1 (SGD-SEMINAR) - CHEMICAL TOXICOLOGY3 |
| SAT 28/8/21 | FM 9.2 (SGD) - CHEMICAL TOXICOLOGY | Describe and discuss the symptoms and signs of acute HIV seroconversion IM 6.1. Define and classify HIV AIDS based on CDC criteria IM 6.2. Describe and discuss the relationship between CD4 count and the risk of oppportunistic infection IM | OG 15.3 FETAL GROWTH RESTRICTION | | aetcom Module 2.4 Working in health care team | | SPORTS |
| SUN 29/8/21 | | | | | | | |
| MON 30/8/21 | CLINICAL POSTING | | FORMATIVE ASSESSMENT | | | SYMPOSIUM FGS TOPICS COMBINED | |

| | | | | | | |
|----------------|---|---|--|--|--|---|
| TUE 31/8/21 | CLINICAL POSTING | | PA 31.2- (SGD)- BREAST- CA BREAST | PA 31.4- (SDL)- BREAST- GYNECOMASTIA | | 2 SGD Opportunistic infections Transplant infections, Immunocompromised MI 8.2 Lab diagnosis of STI (Syphilis, Gonorrhoea, Trichomoniasis, Candidiasis & others) MI 7.1, 7.2 |
| WED 1/9/21 | CLINICAL POSTING | | 1 SGD Congenital Infections TORCHS, HIV, Hepatitis B, Zika & Others MI 1.1 | 1 L Oncogenic Virus PAPOVA, Kaposi, HTLV, EB Virus, HBV, HCV | | PH3.5 To prepare and explain a list of P drugs for a case SGD |
| THU 2/9/21 | CLINICAL POSTING | | 1 SDL + 1 SGD Zoonotic infections Classification Plague, Tuleremia, Bite wound infections, NIPAH & Others MI 8.1 (ALIGNED) | PH3.4 Recognise and report ADR (SGD) | | PA 32.2, 32.3- (L)- ENDOCRINE- THYROIDITIS AND GRAVES CM 8.1 Discuss the epidemiology and control measures of Plague |
| FRI 3/9/21 | CLINICAL POSTING | | PA 32.1- (L)- ENDOCRINE- THYROID TUMOURS | | | PH3.4 Recognise and report ADR (SGD) FM 9.3 (SGD) - HEAVY METAL POISONING1 |
| SAT 4/9/21 | CM 8.1 Discuss the epidemiology and control measures of NIPAH virus infection and Zika virus disease | SU16.1. minimally invasive general surgery. | OG11.1 MULTIPLE PREGNANCY | IM 12.1 Epidemiology and pathogenesis of hypothyroidism and hyperthyroidism IM12.2 Describe and discuss the genetic basis of some thyroid dysfunction IM 12.3 Describe and discuss the physiology of hypothalamopituitary thyroid axis, principles of TFT and alterations in physiological functions | | AETCOM (MICROBIOLOGY COMPETENCY) Demonstrate Confidentiality pertaining to patient's identity MI 8.11, 8.12, 8.14 SPORTS |
| SUN 5/9/21 | | | | | | |
| MON 6/9/21 | CLINICAL POSTING | | PH3.4 Recognise and report ADR (SGD) | | | PA 19.5- (P)- LYMPH NODE- HODGKIN LYMPHOMA |
| TUE 7/9/21 | CLINICAL POSTING | | PA 32.5- (SDL)- ENDOCRINE- PARATHYROID | | | INTERNAL ASSESSMENT II |
| WED 8/9/21 | CLINICAL POSTING | | 1L Emerging & Re emerging Infections & Agents of Bioterrorism MI 8.4 | INTEGRATION With CM National Health programms for Communicable Diseases MI 8.16 | | INTERNAL ASSESSMENT II |

| | | | | | | | |
|----------------|---|---|---|--|--|--|--------|
| THU 9/9/21 | CLINICAL POSTING | | 1 SGD Rational Use of Microbiological Investigations MI 8.13 AND REFLECTIONS | PH5.3 Motivate patients with chronic diseases to adhere medications SGD | PA 32.4- (L)- ENDOCRINE-DIABETES | CM 8.1 IL Discuss the emerging and reemerging infections reported in the last decade and the public health measures to combat it | |
| FRI 10/9/21 | CLINICAL POSTING | | PA 32.4- (L)- ENDOCRINE-DIABETES | | PH5.3 Motivate patients with chronic diseases to adhere medications SGD | FM 9.3 (SGD) - HEAVY METAL POISONING ² | |
| SAT 11/9/21 | FM 9.3 (SGD) - HEAVY METAL POISONING ³ | FORMATIVE ASSESSMENT | OG 16.1 POST PARTUM HEMORRHAGE | | AETCOM (MICROBIOLOGY COMPETENCY) Demonstrate respect for patient's samples sent for investigations, MI 8.11, 8.12, 8.14 | SPORTS | |
| SUN 12/9/21 | | | | | | | |
| MON 13/9/21 | CLINICAL POSTING | | PH5.2 Communicate patient with optimal use of drug therapy SGD | | | PA19.7- (P)- SPLENOMEGALY | |
| TUE 14/9/21 | CLINICAL POSTING | | PA 32.7, 32.8- (SDL)- ENDOCRINE- CUSHINGS , ADRENAL INSUFFICIENCY | | | 2 SGD Opportunistic Infections Transplant infections, infections in Immunocompromised MI 8.2 | |
| WED 15/9/21 | CLINICAL POSTING | | APPLIED MICROBIOLOGY Visit to CSSD MI 1.5 SGD | APPLIED MICROBIOLOGY Visit to Hospital BMW IMAGE MI 8.7 SGD | | PH5.2 Communicate patient with optimal use of drug therapy SGD | |
| THU 16/9/21 | CLINICAL POSTING | | 1 SGD Antimicrobial Resistance & Relevance, Rational use of Antimicrobials MI 1.6 | PH5.4 Explain to patients about the relationship between cost of treatment and patient compliance SGD | PA 32.9- (L)- ENDOCRINE-ADRENAL TUMOURS | CM Essential and counterfeit medicines | |
| FRI 17/9/21 | CLINICAL POSTING | | PA 32.6- (L)- ENDOCRINE-EXOCRINE PANCREAS | | PH5.4 Explain to patients about the relationship between cost of treatment and patient compliance SGD | | |
| SAT 18/9/21 | CM Internal assesment II | SU 7.1, 7.2. surgical audit. Clinical research. | OG 35.1 GYNAECOLOGICAL EXAMINATION | IM 22.1 Enumerate the causes of hypercalcemia and distinguish the features of PTH vs non PTH mediated hypercalcemia IM22.2 Describe the etiology, clinical manifestations, diagnosis and clinical approach to primary hyperparathyroidism | | AETCOM (MICROBIOLOGY COMPETENCY) Demonstrate respect for patient's samples sent for investigations, MI 8.11, 8.12, 8.14 | SPORTS |
| SUN 19/9/21 | | | | | | | |

| | | | | | | | |
|----------------|-------------------------|---|---|--|--|---|--|
| MON 20/9/21 | | | PH5.5 Cautious & judicious use of prescribed drugs SGD | PH5.5 Cautious & judicious use of prescribed drugs SGD | | | PA 20.1- (P) MYELOMA |
| | CLINICAL POSTING | | | | | | |
| TUE 21/9/21 | | | FORMATIVE ASSESSMENT AND REFLECTION | | | | 2 SGD Practicals Environmental Surveillance Bacteriology of Air, Water and Surface MI 8.81 |
| | CLINICAL POSTING | | | | | | |
| WED 22/9/21 | | | INTEGRATION (L) Pandemic management MI | Pandemic management WITH CM (SGD) | | PH 5.6 Public education regarding rational drug use (SGD) | PH5.6 Public education regarding rational drug use (SGD) |
| | CLINICAL POSTING | | | | | | |
| THU 23/9/21 | | | Applied HIC ,MDR precautions and isolation SGD | PH5.7 Legal & ethical aspects of prescribing drugs (SGD) | | SGD- GIT | CM -ATCOMModule 2.3: Health care as a right |
| | CLINICAL POSTING | | | | | | |
| FRI 24/9/21 | | | SGD- RESPIRATORY SYSTEM | | | PH5.7 Legal & ethical aspects of prescribing drugs (SGD) | FM 9.4 (SGD)- ALCOHOL 2 |
| | CLINICAL POSTING | | | | | | |
| SAT 25/9/21 | FM 9.4 (SGD)- ALCOHOL 3 | SU 8.1, 8.2. ethics in surgery. Professionalism & Empathy in surgery | OG24.1 AUB | | | REFLECTION | |
| SUN 26/9/21 | | | | | | | |
| MON 27/9/21 | | | Pandemic management - Therapeutic strategies including new drug development (Longitudinal Integration) | Pandemic management - Therapeutic strategies including new drug development (Longitudinal Integration) | | | PA 23.1- (P)- URINE ANALYSIS |
| | CLINICAL POSTING | | | | | | |
| TUE 28/9/21 | | | PA 23.3- (P)- SEMEN ANALYSIS, RFT, LFT, TFT | | | | Practicals - DOAP DONNING AND DOFFING ,APPROPRIATE USE OF PPE Demonstrate ICP Hand hygiene MI 8.7 DOAP certification Demonstrate use of PPE DOAP certification MI 8.7 |
| | CLINICAL POSTING | | | | | | |
| WED 29/9/21 | | | Choose the most appropriate method of sterilisation and disinfection to be used in specific clinical situations MI 1.5Practicals | Choose the most appropriate method of sterilisation and disinfection to be used in specific surgical practiseMI 1.5Practicals | | including new drug development (L | Pandemic management - Therapeutic strategies including new drug development (Longitudinal Integration) |
| | CLINICAL POSTING | | | | | | |
| THU 30/9/21 | | | BIOMEDICAL WASTE DISPOSAL - SGD 1 | Pandemic management - Therapeutic strategies including new drug development (Longitudinal Integration) | | SGD- MGS | CM 6.1 Designing a research proposal |
| | CLINICAL POSTING | | | | | | |

| | | | | | | | |
|-----------------|---|--|---|---|--|--|--|
| FRI 1/10/21 | | | SGD- FGS | | | Pandemic management - Therapeutic strategies including new drug development (Longitudinal Integration) | FM 9.5 (SGD/ AUTOPSY)- AGRICULTURAL POISONS1 |
| | CLINICAL POSTING | | | | | | |
| SAT 2/10/21 | CM 6.1 Developing a proposal -Literature search | | OG28.1.2FEMALE INFERTILITY | | | FORMATIVE assessment | |
| SUN 3/10/21 | | | | | | | |
| MON 04/10/21 | | | | REFLECTION | | | PA 25.6- (P)- HEPATITIS INTEGRATED |
| | CLINICAL POSTING | | | | | | |
| TUE 5/10/21 | | | PA 27.8- (P)- CARDIAC FUNCTION TESTS IN A/C CORONARY SYNDROME | | | | 2SGD - Perform and Identify the causative agents of infectious diseases MI 1.2 (including candida species)MI DR7.2 |
| | CLINICAL POSTING | | | | | | |
| WED 6/10/21 | | | Identify the etiology of meningitis based on given CSF parameters PA35.3 int with pathology | Identify the microbial agents causing meningitis (Int with IM and Pediatrics JMI5.3 DOAP | | | FORMATIVE ASSESSMENT |
| | CLINICAL POSTING | | | | | | |
| THU 7/10/21 | | | choose the appropriate laboratory test in diagnosis of viral hepatitis with emphasis on viral markers MI3.8 SGD ,case discussion | | | SGD- ENDOCRINE | CM 6.1 Developing research proposal (Group work) |
| | CLINICAL POSTING | | | | | | |
| FRI 8/10/21 | | | SGD- BONE | | | | FM 9.5 (SGD/ AUTOPSY)- AGRICULTURAL POISONS2 |
| | CLINICAL POSTING | | | | | | |
| SAT9/10/21 | FM 9.5 (SGD/ AUTOPSY)- AGRICULTURAL POISONS 3 | | OG 30.1.1PCOS | | | REFLECTION | |
| SUN 10/10/21 | | | | | | | |
| MON 11/10/21 | | | | | | | PA 31.3- (P)- CA BREAST, FIBROADENOMA |
| | CLINICAL POSTING | | | | | | |
| TUE 12/10/21 | | | PA 34.4- (P)- SKIN TUMOURS | | | | SKILL LAB - Demonstrate the appropriate method of collection of samples in the performance of laboratory tests in detection of microbial agents (Blood collection,Swab from infected wound,Aspiration of specimens with aseptic precautions etc) MI 8.10 |
| | CLINICAL POSTING | | | | | | |
| WED 13/10/21 | | | Identify the different modalities for diagnosis of enteric fever.choose the most appropriate test related to duration of illness MI3.4 SGD2 | | | | |
| | CLINICAL POSTING | | | | | | |

| | | | | | | | | |
|-----------------|---|--|--|---|--|--|---------------------------|--|
| THU 14/10/21 | | | | Identify the common aetiological agents of diarrhea and dysentery MI 3.2 SGD 1 | | | SGD- SOFT TISSUE | Developing research proposal (Group work&Presentation)CM |
| | CLINICAL POSTING | | | | | | | |
| FRI 15/10/21 | | | | SGD- HEMATOLOGY | | | | FM 9.6 (SGD)- RESPIRATORY POISONS1 |
| | CLINICAL POSTING | | | | | | | |
| SAT16/10/21 | CM Developing research proposal (Group work&Presentation) | SU 5.4, 8.3. Medicolegal issues in surgical practice | | OG29.1.1FIBROID UTERUS | | | | |
| SUN 17/10/21 | | | | | | | | |
| MON 18/10/21 | | | | | | | | PA 35.3- (P)- CSF EXAMINATION |
| | CLINICAL POSTING | | | | | | | |
| TUE 19/10/21 | | | | REFLECTION | SGD PERIPHERAL SMEAR INTERPRETATION | | | Identify the causative agent of Malaria and filariasis MI 2.6 Practicals |
| | CLINICAL POSTING | | | | | | | |
| WED 20/10/21 | | | | Choose and interpret the results of the Laboratory tests used in UTI MI8.15 SGD | Choose and interpret reports of sputum,Blood and other swabs MI 8.15 SGD | | | INTERNAL ASSESSMENT III |
| | CLINICAL POSTING | | | | | | | |
| THU 21/10/21 | | | | 1 LTransfusion Transmitted Infections | | | SGD HEMOGLOBIN ESTIMATION | Developing research proposal (Group work&Presentation) |
| | CLINICAL POSTING | | | | | | | |
| FRI 22/10/21 | | | | SGD ESR ESTIMATION | | | | FM 9.6 (SGD)- RESPIRATORY POISONS 2 |
| | CLINICAL POSTING | | | | | | | |
| SAT 23/10/21 | FM 14.7,14.8 (SGD/ SKILL) - BLOOD STAIN AND GROUP | SU 11.5. Day case & fast track surgery. | | OG 32.1.1MENOPAUSE | | | | |
| SUN 24/10/21 | | | | | | | | |
| MON 25/10/21 | | | | | | | | INTERNAL ASSESSMENT 3 |
| | CLINICAL POSTING | | | | | | | |
| TUE 26/10/21 | | | | FEEDBACK and Reflection | | | | INTERNAL ASSESSMENT 3 |
| | CLINICAL POSTING | | | | | | | |

| | | | | | | | | |
|-----------------|---|--------------------------|--|---|--|-----------------------|---|--|
| WED 27/10/21 | CLINICAL POSTING | | | choose the interpret appropriate diagnostic tests for diagnosis of HIV IM 6.10,MI 8.13 integrated with Medicine | | INTERNAL ASSESSMENT 3 | | |
| THU 28/10/21 | CLINICAL POSTING | | | FEEDBACK and Reflection | | | CM Proposal presentation | |
| FRI 29/10/21 | CLINICAL POSTING | | | FEEDBACK and Reflection | | | FM 14.10 (SGD/ DOAP-SKILL)- INJURY INTERPRETATION | |
| SAT 30/10/21 | CM 20.3 Describe any event important to health of the community . | SU 11.6. pain management | | OG33.1.1 &33.1.2 PREMALIGNANT LESIONS OF CERVIX&CA CERVIX | | | | |
| SUN 31/10/21 | | | | | | | | |